Raymond Bologna, MD
Urology · Milford, DENPI 1447226337
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (47.3%), speaking fees and education — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Medtronic at 46.7% of the total. Reporting peaked in 2024 at $3,329 and has fallen 89.3% since, to $356 in 2025.
Across 52 payments — averaging $134.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Intuitive Surgical$2K
- Boston Scientific$449
- Bayer$344
- Procept Biorobotics Corporation$207
- Neotract Inc.$155
- plus $845 from 8 others
What the payments were for
- Consulting fees$6409%
- Speaking & faculty fees$1,56022%
- Food & beverage$3,31747%
- Education$1,50021%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 22 | $3,279 |
| Intuitive Surgical | 5 | $1,737 |
| Boston Scientific | 5 | $449 |
| Bayer | 3 | $344 |
| Procept Biorobotics Corporation | 3 | $207 |
| Neotract Inc. | 2 | $155 |
| Sumitomo Pharma America, Inc. | 2 | $152 |
| Rochester Medical Corporation | 3 | $138 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $125 |
| Bard Access Systems, Inc. | 1 | $124 |
| Biotissue Holdings Inc. | 1 | $109 |
| Coloplast | 1 | $100 |
| Caldera Medical, Inc | 2 | $83 |
| Axonics, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTERSTIM$1,682
- DAVINCI XI$1,500
- Nubeqa$344
- Xofigo$229
- GEMTESA$125
- AquaBeam Robotic System$125
- REZUM$124
- AMS 700 CXR RTE KIT$119
- NEOX$109
- CLARIX$109
- GENESIS$100
How this compares
$7,017 in reported general payments places this provider in the 85th percentile of 33 urology providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 263 | $165,685 |
| GemtesaVibegron | 166 | $147,210 |
| Mirabegron ErMirabegron | 13 | $8,898 |
| Estradiol | 129 | $8,199 |
| Trospium Chloride ErTrospium Chloride | 56 | $8,196 |
| Methenamine Hippurate | 78 | $5,169 |
| Oxybutynin Chloride ErOxybutynin Chloride | 257 | $3,950 |
| Trospium Chloride | 39 | $2,156 |
| Tolterodine Tartrate ErTolterodine Tartrate | 29 | $1,810 |
| Solifenacin Succinate | 47 | $1,562 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 68 | $868 |
| Desmopressin Acetate | 13 | $633 |
| Tamsulosin Hcl | 48 | $622 |
| NitrofurantoinNitrofurantoin Macrocrystal | 25 | $517 |
| Oxybutynin Chloride | 25 | $478 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $152 | $147,210166 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 33 urology providers in Delaware.
Other urology in Milford
- Antoinette PtakMilford$2K
- Christopher MitchellWilmington$19K
- Michael LobisWilmington$8K
- Joohyong KimDover$7K
- Thomas DesperitoWilmington$7K
- Christopher VallorosiDover$7K
- Michael ZaragozaDover$6K
- Gregory SpanaDover$5K
- Bruce BengeWilmington$5K
- Elizabeth Kornfield ChadwellSeaford$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.